In addition to in vitro experiments, immunocompetent and immunodeficient mice were used to assess the antitumor effects of cGAS inhibitors, increasing their reliability for potential use in PTCL patients. This evidence concerns the gene CGAS and mature T-cell and NK-cell non-Hodgkin lymphoma.